Tous Actualités
Suivre
Abonner Epigenomics AG

Epigenomics AG

Epigenomics AG Successfully Places Shares at Premium in Capital Increase

Berlin (euro adhoc) -

  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
companies/Diagnostics
12. February 2009 - Epigenomics AG (Frankfurt,
Prime Standard: ECX; ISIN: DE000A0BVT96) successfully placed all 
2,671,088 new shares that were issued in an increase of the share 
capital against contribution in cash and without subscription rights 
that was decided upon yesterday by its Executive and Supervisory 
Boards. A 100% subsidiary of BB MEDTECH AG (Schaffhausen, 
Switzerland) and funds managed by Abingworth LLP (London, UK) 
subscribed for all the new shares.
The issue price was set at EUR 1.94 per share. This constituted a 5% 
premium over and above the volume-weighted average XETRA trading 
prices over the five trading days preceding the announcement of the 
capital increase. The capital raise at this premium leads to gross 
proceeds of approximately EUR 5.18 million. After registration of the
capital increase the signed capital of Epigenomics AG will increase 
from its current EUR 26,723,636 to a total of EUR 29,394,724 
thereafter.
ICF Kursmakler AG  (Frankfurt, Germany) will coordinate the 
registration of the new shares with the Frankfurt Stock Exchange. 
Trout Capital LLC (New York, NY, USA) acted as sole financial advisor
to Epigenomics in this transaction.
Epigenomics intends to apply the proceeds from this transaction 
towards the final stages of product development and commercialization
of its most advanced product, a blood-based molecular diagnostic test
for the early detection of colorectal cancer. Proceeds will also be 
used for clinical research and product development in Epigenomics' 
lung cancer and prostate cancer programs.
"We are very pleased that in BB MEDTECH and Abingworth LLP we have  
major shareholders that share our vision and strategic direction to 
develop Epigenomics into a leading cancer molecular diagnostics 
company over the next several years" commented Geert Nygaard, Chief 
Executive Officer of Epigenomics on the transaction. "These investors
have  unique expertise in the diagnostics and medical device industry
and a team of very experienced specialists in this sector. This will 
help medium and long-term to provide Epigenomics with the financial 
stability that we need for the successful commercialisation of our 
products."
"We believe in a continued dynamic development of the molecular 
diagnostics market segment in the years to come. After the 
development of technological platforms in the past several years, 
content based on these technologies like cancer tests will be in the 
focus in the future. Epigenomics may be one of those specialized 
companies who get to market early", said Laura Rossi, head of the BB 
MEDTECH management team.
"We are particularly pleased to have raised the capital at a share 
price significantly above the most recent rights issue price of 
February 2008 despite the extremely challenging capital markets 
environment and global financial crisis. This is testament to the 
solid fundamentals and excellent progress we have made in executing 
our business plan", Geert Nygaard added.
After settlement, the BB MEDTECH group will have doubled its stake in
Epigenomics to about 14.9% from about 7.4% before the transaction and
will be Epigenomics' second largest shareholder after Federated 
Investors Inc. (Pittsburgh, PA, U.S.A.). Funds managed by Abingworth 
LLP will own about 11.1%.
About Epigenomics
Epigenomics is a molecular diagnostics company with a focus on the 
development of novel products for cancer. Using DNA methylation 
biomarkers, Epigenomics' tests in development aim at diagnosing 
cancer at an early stage before symptoms occur and thereby may reduce
mortality from this dreaded disease.
Epigenomics' product pipeline contains a validated biomarker for the 
early detection of colorectal cancer in blood plasma, and further 
proprietary DNA methylation biomarkers at various stages of 
development for prostate and lung cancer detection in urine, blood 
and bronchial lavage specimens. Epigenomics' biomarker mSEPT9 for the
early detection of colorectal cancer in a simple blood sample 
demonstrated continuously highest performance in multiple clinical 
studies with in total about 3,500 individuals tested.
For development and global commercialization of in vitro diagnostic 
test products, Epigenomics pursues a non-exclusive partnering 
strategy. Strategic diagnostics industry partners include Abbott 
Molecular, Philips, Sysmex Corporation and Quest Diagnostics for 
diagnostics test products, and QIAGEN N.V. for sample preparation 
solutions and research products.
Partners in the health care industry and the biomedical research 
community can access Epigenomics' portfolio of proprietary DNA 
methylation technologies and biomarkers protected by more than 150 
patent families through research products, Biomarker Services, IVD 
Development Collaborations, and Licensing. The company is 
headquartered in Berlin, Germany, and has a wholly owned subsidiary 
in Seattle, WA, U.S.A. For more information, please visit 
Epigenomics' website at www.epigenomics.com.
Epigenomics' legal disclaimer. This communication expressly or 
implicitly contains certain forward-looking statements concerning 
Epigenomics AG and its business. Such statements involve certain 
known and unknown risks, uncertainties and other factors which could 
cause the actual results, financial condition, performance or 
achievements of Epigenomics AG to be materially different from any 
future results, performance or achievements expressed or implied by 
such forward-looking statements. Epigenomics AG is providing this 
communication as of this date and does not undertake to update any 
forward- looking statements contained herein as a result of new 
information, future events or otherwise.
Disclaimer relating to US Securities Laws. The sale of the common 
stock will not be registered under the Securities Act of 1933, as 
amended (the "Securities Act"), or applicable state securities laws. 
The shares will be sold pursuant to applicable exemptions from the 
registration requirements of the Securities Act. Unless registered, 
the shares may not be offered or sold in the United States except 
pursuant to an exemption from the registration requirements of the 
Securities Act and applicable state securities laws. This news 
release does not constitute an offer to sell or the solicitation of 
an offer to buy the securities.
end of announcement                               euro adhoc

Further inquiry note:

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade

Plus de actualités: Epigenomics AG
Plus de actualités: Epigenomics AG